oseltamivir / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oseltamivir / Generic mfg.
ACTRN12615000638538: The Role of Oseltamivir During Influenza Outbreaks in Aged-care Facilities in the Context of Optimal Influenza Vaccination and Infection Control

Not yet recruiting
3
74
 
Children's Hospital, Westmead: National Centre for Immunisation Research and Surveillance, National Health and Medical Research Council
Influenza in Residential Aged Care Facilities, Surveillance systems for influenza in Residential Aged Care Facilities
 
 
ChiCTR-IPR-14005665: REDUNING, a kind of traditional Chinese medicine injections, in the treatment of influenza high fever: A randomized controlled clinical trial

Recruiting
3
480
 
REDUNING injection and Phosphate oseltamivir capsules placebo ;Phosphate oseltamivir capsules and REDUNING injection placebo
Tianjin University of Traditional Chinese Medcine; Jiangsu Kanion Pharmaceutical Co., Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd.
influenza
 
 
IFLDCRct, ChiCTR-IPR-15007322: Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study about Lingdancao Granules in the Treatment of Seasonal Influenza

Not yet recruiting
3
318
 
Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day ;Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day ;Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day
The 1st Affiliated Hospital of Guangzhou Medical University; The 1st Affiliated Hospital of Guangzhou Medical University, Project
Seasonal Influenza
 
 
NCT04558463: The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19

Recruiting
3
100
RoW
Favipiravir, Avigan® (favipiravir), Oseltamivir 75mg, Oseltamivir
Indonesia University
Covid19
09/20
10/20
NCT03520049: Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia

Recruiting
3
30
Canada
Oseltamivir, Oseltamivir phosphate, Tamiflu®, Placebo
Unity Health Toronto, Li Ka Shing Knowledge Institute, University of Toronto
Immune Thrombocytopenia
09/21
09/21
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed
3
750
RoW
ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273
Guangdong Raynovent Biotech Co., Ltd
Influenza A
04/23
05/23
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
NCT06507813: Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza

Recruiting
3
165
RoW
ADC189 tablets, Baloxavir Marboxil tablets, Placebo of ADC189 tablets, Placebo of Baloxavir Marboxil tablets, ADC189 granules, Placebo of ADC189 granules, Placebo of Oseltamivir granules, Oseltamivir granules
Jiaxing AnDiCon Biotech Co.,Ltd
Influenza Type A, Influenza Type B
12/24
06/25
NCT03901001: Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza

Recruiting
3
160
RoW
sirolimus and oseltamivir, Oseltamivir
Chinese University of Hong Kong
Influenza
10/25
12/25
NCT03900988: Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia

Recruiting
3
160
RoW
N-acetyl cysteine, 5% Dextrose
Chinese University of Hong Kong
Influenza
10/25
12/25
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
COMBO 1, NCT04327791: COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

Recruiting
2/3
60
US
Baloxavir, Placebos
Bassett Healthcare, Genentech, Inc., Viroclinics Biosciences B.V.
Influenza
06/24
06/25
NCT05170009: Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

Terminated
2/3
2
US
Baloxavir Marboxil, Xofluza, Placebo, Oseltamivir, Tamiflu
Weill Medical College of Cornell University, Genentech, Inc.
Influenza
01/24
02/24

Download Options